Institut Universitari Dexeus-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

2023

  1. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

2018

  1. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128

  2. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

    Therapeutic Advances in Medical Oncology, Vol. 10

2017

  1. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768

2016

  1. Circulating melanoma exosomes as diagnostic and prognosis biomarkers

    Clinica Chimica Acta, Vol. 454, pp. 28-32

2015

  1. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

    Melanoma Research, Vol. 25, Núm. 6, pp. 486-495

  2. Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 study

    PLoS ONE, Vol. 10, Núm. 4

  3. Immune checkpoint inhibitors: Therapeutic advances in melanoma

    Annals of Translational Medicine, Vol. 3, Núm. 18